Home/Filings/4/0001214504-25-000007
4//SEC Filing

PEPIN RONALD 4

Accession 0001214504-25-000007

CIK 0000744218other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 4:06 PM ET

Size

11.5 KB

Accession

0001214504-25-000007

Insider Transaction Report

Form 4
Period: 2025-12-15
PEPIN RONALD
Sr. VP & CBO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-15$9.02/sh+8,333$75,1349,097 total
  • Exercise/Conversion

    Common Stock

    2025-12-15$2.78/sh+11,000$30,58020,097 total
  • Exercise/Conversion

    Incentive Stock Option (right to buy)

    2025-12-158,3335,000 total
    Exercise: $9.02Exp: 2028-06-13Common Stock (8,333 underlying)
  • Exercise/Conversion

    Incentive Stock Option (right to buy)

    2025-12-1511,0000 total
    Exercise: $2.78Exp: 2029-06-19Common Stock (11,000 underlying)
Footnotes (4)
  • [F1]On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
  • [F2]Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
  • [F3]As of June 13, 2022, the option is fully vested.
  • [F4]As of June 19, 2023, the option is fully vested.

Issuer

Celldex Therapeutics, Inc.

CIK 0000744218

Entity typeother

Related Parties

1
  • filerCIK 0001214504

Filing Metadata

Form type
4
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:06 PM ET
Size
11.5 KB